Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer.

× No keyword cloud information.

15 in total

Review 1. Current approaches to the treatment of metastatic brain tumours.

Authors: Taofeek K Owonikoko; Jack Arbiser; Amelia Zelnak; Hui-Kuo G Shu; Hyunsuk Shim; Adam M Robin; Steven N Kalkanis; Timothy G Whitsett; Bodour Salhia; Nhan L Tran; Timothy Ryken; Michael K Moore; Kathleen M Egan; Jeffrey J Olson
Journal: Nat Rev Clin Oncol Date: 2014-02-25 Impact factor: 66.675

2. Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

Authors: Sai-Hong Ignatius Ou; Karen R Sommers; Michele C Azada; Edward B Garon
Journal: Oncologist Date: 2015-01-07

Review 3. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.

Authors: Ivana Sullivan; David Planchard
Journal: Ther Adv Med Oncol Date: 2016-01 Impact factor: 8.168

Review 4. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.

Authors: Alessia Spagnuolo; Matteo Muto; Fabio Monaco; Giuseppe Colantuoni; Cesare Gridelli
Journal: Transl Lung Cancer Res Date: 2019-12

5. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Authors: Helen Y Zou; Luc Friboulet; David P Kodack; Lars D Engstrom; Qiuhua Li; Melissa West; Ruth W Tang; Hui Wang; Konstantinos Tsaparikos; Jinwei Wang; Sergei Timofeevski; Ryohei Katayama; Dac M Dinh; Hieu Lam; Justine L Lam; Shinji Yamazaki; Wenyue Hu; Bhushankumar Patel; Divya Bezwada; Rosa L Frias; Eugene Lifshits; Sidra Mahmood; Justin F Gainor; Timothy Affolter; Patrick B Lappin; Hovhannes Gukasyan; Nathan Lee; Shibing Deng; Rakesh K Jain; Ted W Johnson; Alice T Shaw; Valeria R Fantin; Tod Smeal
Journal: Cancer Cell Date: 2015-07-02 Impact factor: 31.743

6. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.

Authors: Justin F Gainor; Carol A Sherman; Kathryn Willoughby; Jennifer Logan; Elizabeth Kennedy; Priscilla K Brastianos; Andrew S Chi; Alice T Shaw
Journal: J Thorac Oncol Date: 2015-02 Impact factor: 15.609

High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer.

Review 1. Current approaches to the treatment of metastatic brain tumours.

2. Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

Review 3. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.

Review 4. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.

5. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

6. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.

Review 7. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.

Review 8. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.

Review 9. Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

10. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.